Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model

Gene Therapy

Volumn 5, Issue 11, 1998, Pages 1538-1544

  Xing, X ^a   Zhang, S ^a   Chang, J Y ^a,d   Tucker, S D ^b   Chen, H ^a   Huang, L ^c   Hung, M C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Antigenics Inc   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

Author keywords

Cationic liposome; E1A; Gene therapy; HER 2 neu; Ovarian cancer

Indexed keywords

LIPID; LIPOSOME; VIRUS PROTEIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CLINICAL TRIAL; DNA METHYLATION; FEMALE; GENE REPRESSION; GENE THERAPY; GENE TRANSFER; HEART; KIDNEY; LIVER; LUNG; MOUSE; NONHUMAN; ONCOGENE NEU; OVARY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SAFETY; SPLEEN; UTERUS;

ADENOVIRIDAE; ANIMALIA;

EID: 0031768405     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300771     Document Type: Article

References (42)

1. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319: 226-230.
2. Hung MC et al. Molecular cloning of the neu gene: absence of gross structural alterations in oncogenic alleles. Proc Natl Acad Sci USA 1986; 83: 261-264.
3. Yamamoto T et al. Similarity of protein encoded by the human c-frbB-2 gene to epidermal growth factor receptor. Nature 1986; 319: 230-232.
4. Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 233: 177-182.
5. Slamon DJ et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
6. Van de Vijver M et al. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 1987; 7: 2019-2023.
7. Berchuck A et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087-4091.
8. Dougall WC, Greene MI. Biological studies and potential therapeutic application of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein. Cell Biophysics 1994; 24-25: 209-218.
9. Katsumata M et al. Prevention of breast tumor development in vivo by down-regulation of the pl85neu receptor. Nature Med 1995; 1: 644-648.
10. Yu D, Scorsone K, Hung M-C. Adenovims type 5 E1A gene products act as transformation suppressors of the neu oncogene. Mol Cell Biol 1991; II: 1745-1750.
11. Matin A, Hung M-C. Negative regulation of the neu promoter by the SV40 large T antigen. Cell Growth Differ 1993; 4: 1051-1056.
12. Zhang Y, Yu D, Xia W, Hung M-C. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene 1995; 10: 1947-1954.
13. Hung M-C et al. HER-2/neu-targeting gene therapy - a review. Gene 1995; 159: 65-71.
14. Xing X et al. Mutant SV40 Large T as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer. Cancer Gene Ther 1996; 3: 168-174.
15. Yu D et al. Liposome-mediated El A gene transfer as therapy for ovarian cancers that overexpress HER-2/neu. Oncogene 1995; 11: 1383-1388.
16. Chang JY et al. The tumor suppressing activity of E1A in HER27 neu-overexpressing breast cancer. Oncogene 1997; 14: 561-568.
17. Chang JY, Xia W, Shao RP, Hung MC. Inhibition of intratracheal lung cancer development by systemic delivery of ElA. Oncogene 1996; 13: 1405-1412.
18. Baselga J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
19. Yu D et al. Transcriptional repression of the neu proto oncogene by the Adenovirus 5 El A gene products. Proc Natl Acad Sci USA 1990; 87: 4499-4503.
20. Yan D-H, Chang L-S, Hung M-C. Repressed expression the HER-2/ neu/c-erbB-2 proto-oncogene by the adenovirus E1A gene products. Oncogens 1991; 6: 343-345.
21. Yu D et ai. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by El A. Cancer Res 1993; 53: 891-898.
22. Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991; 178: 280-285.
23. Xing X et al. Safety studies of the intraperitoneal injection of ElA-liposome complex in mice. Gene Therapy 1997; 4: 238-243.
24. Ruley HE. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 1983; 304: 602-606.
25. Moran E, Mathews MB. Multiple functional domains in the adenovirus EIA gene. Cell 1987; 48: 177-178.
26. Deng C et al. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996; 274: 2057-2059.
27. Whyte P, Williamson MM, Harlow E. Cellular targets for transformation by the adenovirus EIA protein. Cell 1989; 56: 67-75.
28. Geisberg JV, Chen JL, Ricciardi RP. Subrogions of the adenovirus EIA transactivation domain target multiple components of the TFIIID complex. Mol Cell Biol 1995; 15: 6283-6290.
29. Agoff SN, Wu B. CBF mediates adenovirus Ela trans-activation by interaction at the C-terminal promoter targeting domain of conserved region 3. Oncogene 1994; 9: 3707-3711.
30. Bondesson M, Mannervik M, Akusjarvi G, Svensson C. An adenovirus EIA transcriptional represser domain functions as an activator when tethered to a promoter. Nucleic Acids Res 1994; 22: 3053-3060.
31. Chen H et al. Mapping of adenovirus 5 EIA domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene 1997; 14: 1965-1971.
32. Kurebayashi J et al. Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ. Cancer Res 1993; 53: 2178-2187.
33. Parker SE et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther 1996; 3: 175-185.
34. Nable G et al. Direct gene transfer with DNA-Iiposome complexes in melanoma: expression, biological activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 1130711310.
35. Caplen NJ et al. Liposome-mediated CFTR gene transfer to the natal epithelium of patients with cystic fibrosis. Nature Med 1995; 1: 39-46.
36. Nable EG et al. Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Hum Gene Ther 1994; 5: 1089-1094.
37. Yang JP, Huang L. Direct gene transfer to mouse melanoma by intratumor injection of free DNA. Gene Therapy 1996; 3: 542-548.
38. Fattaey A, Harlow E, Helin K. Independent regions of adenovirus EIA are required for binding to and dissociation of E2Fprotein complexes. Mol Cell Biol 1993; 13: 7267-7277.
39. Ikeda MA, Nevin JR. Identification of distinct roles for separate EIA domains in the disruption of E2F complexes. Mol Cell Biol 1993; 13: 7029-7035.
40. Lee WS et al. Adenovirus EIA activation domain binds to the basic repeat in the TATA box transcription factor. Cell 1991; 67: 365-376.
41. Liu F, Green MR. A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus EIA protein. Cell 1990; 61: 1217-1224.
42. Xia W et al. Strong correlation of c-erbB-2 overexpression and overall survival of the patients with oral squamous cell carcinoma. Clin Cancer Res 1997; 3. 3-9.